C4 Therapeutics GAAP EPS of -$0.20 beats by $0.06, revenue of $6.15M beats by $1.73M
Source: SeekingAlpha
2026-05-12 07:10:46 ET
More on C4 Therapeutics
- C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact
- C4 Therapeutics, Inc. (CCCC) Presents at TD Cowen 46th Annual Health Care Conference - Slideshow
- C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates
- Seeking Alpha’s Quant Rating on C4 Therapeutics
Read the full article on Seeking Alpha
For further details see:
C4 Therapeutics GAAP EPS of -$0.20 beats by $0.06, revenue of $6.15M beats by $1.73M
C4 Therapeutics Inc.
NASDAQ: CCCC
CCCC Trading
-9.02% G/L:
$3.835 Last:
1,037,019 Volume:
$4.15 Open:
CCCC Latest News
May 12, 2026 07:00:00 am
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
CCCC Stock Data
$276,378,373
60,917,496
0.2%
27
N/A
Biotechnology & Life Sciences
Healthcare
US
Watertown
